|  | 
| MechanismSLCO3A1 agonists | 
| Active Org.- | 
|  | 
|  | 
|  | 
| Drug Highest PhasePhase 3 | 
| First Approval Ctry. / Loc.- | 
| First Approval Date- | 
| Target- | 
| MechanismNitric oxide donors | 
| Active Org.- | 
|  | 
| Active Indication- | 
|  | 
| Drug Highest PhaseDiscontinued | 
| First Approval Ctry. / Loc.- | 
| First Approval Date- | 
| Target- | 
| MechanismAngiogenesis inducers [+1]  | 
| Active Org.- | 
|  | 
| Active Indication- | 
|  | 
| Drug Highest PhaseDiscontinued | 
| First Approval Ctry. / Loc.- | 
| First Approval Date- | 
Phase 1 Pharmacokinetic and Pharmacodynamic Responses to Oral L-Citrulline in Patients With Sickle Cell Disease
To evaluate PK and PD responses to L-citrulline given orally for four weeks to patients with sickle cell disease who are otherwise healthy.
Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral L-Citrulline Compared to Placebo in Patients Taking Background Simvastatin 40 mg qD and With Peripheral Arterial Disease Including Intermittent Claudication
To prove the combination of L-citrulline with simvastatin leads to greater improvement in the symptoms of peripheral arterial disease (PAD) than simvastatin alone by evaluating oral L- citrulline or placebo against simvastatin for improvement in treadmill walking distance in patients, 40-75 years of age, who have PAD with intermittent claudication.
Phase II, Single Center, Non-Controlled, Open-Label Study of Liposomal Prostaglandin E1 (Liprostin) as Adjunct Therapy With Lower Limb Angioplasty in Patients With Ischemic and Non-Ischemic Peripheral Arterial Occlusive Disease
This is the first clinical research trial in which intravenous Prostaglandin E1 (PGE1 is a vasoactive hormone) will be used as supportive treatment along with the angioplasty procedure to treat or open up a blocked artery within one lower limb or the most affected of two limbs in subjects with Peripheral Arterial Occlusive Disease.
100 Clinical Results associated with Endovasc, Inc.
0  Patents (Medical) associated with Endovasc, Inc.
100 Deals associated with Endovasc, Inc.
100 Translational Medicine associated with Endovasc, Inc.